Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
63
resultados
Última actualización
16/03/2025 [07:19:00]
Resumen de: AU2023347307A1
The disclosure relates to lemborexant, a dual orexin receptor antagonist, and compositions and methods for use in treatment of Alzheimer's disease (AD), e.g., in a subject who has AD or who is at risk for developing AD.
Resumen de: WO2025054610A1
Dementia is a brain disease which results in irreversible and progressive loss of cognition and motor activity. Despite global efforts, there are no simple and reliable diagnosis or treatment options. Embodiments of the disclosed technology provide an aptamer-based graphene field-effect transistor (GFET) biosensor platform that has high sensitivity and precision across a range of epidemiologically significant Alzheimer's disease and Parkinson's disease variants, and enables at-home and point-of-care (POC) testing for neurodegenerative diseases. An example method of detecting for detecting a molecular biomarker for dementia of a subject includes receiving a biological sample comprising the molecular biomarker for dementia, contacting the biological sample with a biosensor device comprising a GFET-based detection chip, and detecting a presence of the molecular biomarker for dementia in the biological sample.
Resumen de: WO2025050415A1
Disclosed in the present invention is the use of peripheral blood macrophages in the preparation of a reagent and/or a drug for the diagnosis, prognosis and treatment of Alzheimer's disease (AD). The present invention will open new doors for a better understanding of the disease mechanisms of Alzheimer's disease and may guide development in new directions for early diagnosis, prognosis and treatment, so as to enable early prevention and treatment of Alzheimer's disease.
Resumen de: US2025084157A1
The invention relates to antibodies, antibody fragments and binding agents that specifically recognize oligomeric tau but do not bind to monomeric tau, fibrillar tau or non-disease associated forms of tau.
Resumen de: WO2023214324A1
The present invention relates to a method for diagnosing neurodegenerative diseases, wherein said method comprises measuring the JNK3 levels in a biological sample selected from plasma, CSF, and saliva. In an embodiment, said method also comprises measuring P-JNK3.
Resumen de: MX2024009492A
Disclosed herein are methods of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD or another disorder associated with amyloid accumulation in the brain.
Resumen de: US2025064417A1
Disclosed are methods for using regional tau PET scans for identifying a subject having or suspected of having, diagnosing, and treating Alzheimer's disease. The methods are particularly useful for treating and diagnosing a patient as susceptible and at risk for developing amyloid-beta and cognitive dysfunction using tau-PET imaging based on regional tau PET measures.
Resumen de: CN118731373A
The invention belongs to the field of biological medicine, and particularly relates to a combination for joint detection of Alzheimer's disease biomarkers and application. The invention provides an application of a biomarker group in detection of Alzheimer's disease, and is characterized in that the biomarker group comprises: a) at least two of APOE4, GDF-15, UCH-L1 and PF4; or b) at least one of APOE4, GDF-15, UCH-L1 and PF4, as well as a phosphorylated Tau protein and a total Tau protein. The invention also provides a kit for detecting the Alzheimer's disease. According to the invention, more effective detection and diagnosis of the Alzheimer's disease are facilitated, and a new path is provided for detection and prevention of AD.
Resumen de: WO2025046049A1
The present invention relates to molecules that are capable of binding to amyloid fibril aggregates. The invention further describes methods for detecting the presence of amyloid fibril aggregates in a sample or a subject. The invention even further describes methods for treating pathologies caused by amyloid fibril aggregates.
Resumen de: AU2025201059A1
The invention provides anti-Tau antibodies and methods of using the same.
Resumen de: EP4516923A1
The present application relates to a digested DDIT4L product as a diagnostic marker for Alzheimer's disease, and use thereof in diagnosing Alzheimer's disease. In particular, the present application relates to use of a substance for detecting a digested intron retention (DIR) product encoding DNA-damage-inducible transcript 4 like (DDIT4L) in a sample of a subject in preparing a product for diagnosing Alzheimer's disease or a mild cognitive disorder and/or assessing (e.g., grading or staging) cognitive disorder progression, a related product thereof, and a method for screening a medicament using the DIR product.
Resumen de: US2022397580A1
The present disclosure relates generally to the field of neurology. In particular, the disclosure relates to a method of detecting a neurodegenerative disease in a subject and methods of treatment thereof. The methods include detecting the level of an exosome-bound aggregated biomarker in a sample obtained from the subject, wherein an increased level of the exosome-bound aggregated biomarker as compared to a reference indicates that the subject is suffering from a neurodegenerative disease. Also described are methods for detecting a subject at risk of developing amyloidosis or a neurodegenerative disease, methods for detecting and treating amyloidosis or a neurodegenerative disease in a subject, and methods of determining the aggregation state of a biomarker in a sample.
Resumen de: AU2023329330A1
Provided herein are antibodies, or fragments thereof, that specifically bind to a microtubule-binding region (MTBR) of tau, and uses thereof. Further provided are methods of detecting species of MTBR in blood or cerebral spinal fluid, and the use of such detection for diagnosing, prognosing, or staging pathological features and/or clinical symptoms of tauopathies, and to choose treatments appropriate for a given disease stage.
Resumen de: US2025067731A1
The present invention provides improved and minimally invasive biomarker-based diagnostics for synucleinopathies (e.g., Parkinson's disease (PD)). The invention further provides assays and methods for analysis of biological samples, for the evaluation and determination of characteristics pertaining to pathological processes associated with α-synuclein, and to methods for determining the suitability of analytical agents for diagnosis of synucleinopathies. More specifically, the invention in embodiments thereof provides improved methods comprising specific detection and quantification of α-synuclein-based biomarkers from low volumes of biological samples.
Resumen de: WO2025040574A1
Alzheimer's disease is strongly linked to biological aging and bioenergetic abnormalities. Systemic dysregulation of metabolism is a hallmark of the physiological decline of tissues with age. We aimed to explore untargeted metabolomic profiling of blood samples from amyloid-positive people to distinguish individuals who progressed to cognitive decline from those who remained cognitively intact despite having amyloid deposits in the brain. A minimal signature of 9 metabolites identified decliners and non-decliners of cognitive function in participants with an amyloid load. These findings are of clinical importance as they suggest that a metabolic fingerprint may help to predict patients who will develop cognitive decline. Due to the high prevalence of brain amyloid-positivity in older adults, identifying adults who will have cognitive decline will enable the development of personalized and early interventions. The present invention relates to an in vitro method for predicting cognitive decline in a subject comprising the step of determining the level of at least one metabolite selected in the group consisting of 3-hydroxybutyrate, acetone, triglyceride 48:3, glucose, citrate, succinate, methionine, serine, sphingomyelin d18:1/C26:0 in a biological sample obtained from the subject.
Resumen de: US2025064417A1
Disclosed are methods for using regional tau PET scans for identifying a subject having or suspected of having, diagnosing, and treating Alzheimer's disease. The methods are particularly useful for treating and diagnosing a patient as susceptible and at risk for developing amyloid-beta and cognitive dysfunction using tau-PET imaging based on regional tau PET measures.
Resumen de: EP4512413A1
Use of an interleukin 27 (IL-27) protein in preparation of a product for treating and/or delaying Alzheimer's disease (AD) is provided, belonging to the technical field of biomedicine. The IL-27 protein refers to a recombinant IL-27 protein targeting a therapeutic target II,-27, and is selected from the group consisting of a mouse-derived IL-27 protein and a human-derived IL-27 protein, as well as a mammalian IL-27 protein other than the mouse-derived IL-27 protein and the human-derived IL-27 protein. The recombinant IL-27 protein can effectively alleviate the AD caused by Aβ deposition, and can selectively bind to a target receptor, thereby ensuring an accuracy of test results. The protein receptor is highly expressed in the dentate gyrus region of hippocampus, and guarantees drug targeting to the greatest extent. The recombinant IL-27 protein also shows desirable application prospects, can quickly and effectively improve and alleviate behaviors such as the memory impairment in mice with AD, and has a clinical transformation value.
Resumen de: US2022267776A1
Aspects of the disclosure relate to compositions and methods for the diagnosis and/or treatment of certain neurodegenerative diseases, for example those diseases associated with repeat-associated non-ATG (RAN) translation proteins, such as Alzheimer's disease (AD). In some embodiments, the disclosure relates to identifying a subject having a RAN protein-associated disease by detecting expression or activity of repeat-associated non-ATG (RAN) translation proteins (e.g., RAN proteins). In some embodiments, the disclosure relates to methods of treating a RAN protein-associated disease by administering to a subject in need thereof an agent that reduces expression or activity of RAN proteins.
Resumen de: US2025051429A1
Herein is reported an antibody that binds to human A-beta protein, wherein the antibody comprises a heavy chain variable domain (VH) and a light chain variable domain comprising CDRs selected from (1) CDRs of SEQ ID NO: 85, 86, 87, 81, 82 and 83; or (2) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 83; or (3) CDRs of SEQ ID NO: 85, 86, 87, 81, 82 and 91; or (4) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 91.
Resumen de: WO2025037271A1
Provided herein are methods and assays for detecting central nervous system (CNS)-derived tau peptides in blood-based samples from subjects, involving the use of a capture antibody that binds to a tau epitope, and a detection antibody that binds to an epitope comprising amino acids residues that span the junction of Exon 4 and Exon 5 of CNS-derived tau.
Resumen de: US2025059584A1
Provided are methods for diagnosing and/or treating Alzheimer's disease. Also provided are biomarkers, and combinations of biomarkers, that are diagnostic for the presence and progression of Alzheimer's disease, and treatment thereof.
Resumen de: US2025060376A1
The present application relates to a digested DDIT4L product as a diagnostic marker for Alzheimer's disease, and use thereof in diagnosing Alzheimer's disease. In particular, the present application relates to use of a substance for detecting a digested intron retention (DIR) product encoding DNA-damage-inducible transcript 4 like (DDIT4L) in a sample of a subject in preparing a product for diagnosing Alzheimer's disease or a mild cognitive disorder and/or assessing (e.g., grading or staging) cognitive disorder progression, a related product thereof, and a method for screening a medicament using the DIR product.
Resumen de: US2025060377A1
Disclosed are p53 peptides and their use as biomarkers in the diagnosis and/or prognosis of Alzheimer's disease (AD) in a biological sample. The invention also provides for a diagnostic method based on a highly accurate mass spectrometry analysis for the diagnosis of Alzheimer's disease at the pre-clinical and prodromal stages of the disease and for the prognosis of cognitive decline in a subject, by quantitating the levels of said p53 peptides specifically in human plasma of patients.
Resumen de: WO2025038979A1
Material compositions and/or methods useful for the prophylaxis and/or treatment of protein depletion (proteinopenia) are provided, including material compositions that retains native function of a peptide/protein while limiting and/or preventing amyloid formation and/or aggregation of said peptide/protein. Material compositions and formulations for enhancing peptide/protein solubility, stability, circulation time, receptor interaction, brain penetrance, CSF half-life, facilitating peptide/protein synthesis and purification are also provided.
Nº publicación: EP4508433A1 19/02/2025
Solicitante:
UNIV OF EASTERN FINLAND [FI]
University of Eastern Finland
Resumen de: WO2023198960A1
The present disclosure relates to a method for determining a risk of development or risk of presence of Alzheimer's disease in a human subject comprising analyzing an activity of a PIEZO1 receptor. The disclosure also relates to a kit for determining a risk of development or risk of presence of Alzheimer's disease according to the present method. The disclosure also relates to an in vitro use of a PIEZO1 receptor as a biomarker and and determination of intracellular calcium level as a biomarker for determining a risk of development or risk of presence of Alzheimer's disease in a human subject.
BOPI
Sede Electrónica
